Navigation Links
Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
Date:4/1/2008

HILTON HEAD ISLAND, S.C., April 1 /PRNewswire/ -- Dr. Roger Kenneth Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to the funder community, including funding initiatives such as the Grand Challenges in Global Health initiative. The monies would be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World AIDS Day Conference in China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.

"I am thinking in terms of problem solving. Traditional commercial drug design and projects funding from the NIH has completely ignored this approach to date," stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Dr. Hershline is hopeful that the foundation community, including the Grand Challenges in Global Health initiative, looks into the work and progress that he has made towards solving this problem and fills the gap in funding.

Dr. Hershline has a doctorate degree in drug design and a medical degree. Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially lifesaving invention, LiSAVIOR remains completely un-funded.

Interested parties can contact Dr. Roger Kenneth Hershline, PhD, MD, thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail: P.O. Box 23467, Hilton Head Is., SC, 29925, fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.

Web site: http://www.curehiv.us

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
2. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Genmab Reaches Milestones in Ofatumumab Collaboration
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Fralex reaches 100th patient milestone in fibromyalgia study
7. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
8. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
9. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... their findings on what they believe could be a new and helpful biomarker ... new research. Click here to read it now. , Biomarkers are ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):